Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 18, 2022 08:00 ET | Source: 89bio, Inc.

89bio Announces Completion of Enrollment in ENLIVEN, the Phase 2b Trial of Pegozafermin for the Treatment of NASH

SAN FRANCISCO, Aug. 18, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
August 11, 2022 08:00 ET | Source: 89bio, Inc.

89bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update

- Reported positive topline results from ENTRIGUE Phase 2 trial of pegozafermin in severe hypertriglyceridemia patients; initiation of Phase 3 trial expected in the first half of 2023 - - ENTRIGUE...
July 05, 2022 08:00 ET | Source: 89bio, Inc.

89bio Announces Closing of its Upsized $94.5 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants

SAN FRANCISCO, July 05, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative...
June 29, 2022 01:47 ET | Source: 89bio, Inc.

89bio, Inc. Announces Upsized Pricing of $94.5 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants

SAN FRANCISCO, June 29, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative...
June 28, 2022 16:02 ET | Source: 89bio, Inc.

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock, Pre-Funded Warrants and Warrants

SAN FRANCISCO, June 28, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative...
June 28, 2022 16:01 ET | Source: 89bio, Inc.

89bio Reports Positive Topline Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)

- Trial met primary endpoint demonstrating statistically significant and clinically meaningful reductions across all doses (63% at the 27mg QW dose; p<0.001) in triglycerides (TG) from baseline;...
June 21, 2022 08:00 ET | Source: 89bio, Inc.

89bio to Present Additional Pegozafermin Data at EASL International Liver Congress™ 2022

SAN FRANCISCO, June 21, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
May 11, 2022 16:05 ET | Source: 89bio, Inc.

89bio Reports First Quarter 2022 Financial Results and Provides Corporate Update

- ENTRIGUE Phase 2 trial of pegozafermin in severe hypertriglyceridemia (SHTG) patients remains on track with topline data expected in the second quarter of 2022 - - ENLIVEN Phase 2b NASH trial...
May 03, 2022 08:00 ET | Source: 89bio, Inc.

89bio to Participate in Upcoming Investor Conferences

SAN FRANCISCO, May 03, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
April 26, 2022 08:00 ET | Source: 89bio, Inc.

89bio to Host Key Opinion Leader Webinar on Severe Hypertriglyceridemia (SHTG)

SAN FRANCISCO, April 26, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...